Q3 2020 Sales Performance

Belantamab mafodotin the first approved anti-BCMA agent for multiple myeloma Approved in US and EU based on the benefit/risk profile in heavily R/R MM ADC Lysosome BCMA Malignant Plasma Cell BCMA ADCC/ADCP Fo Receptor Effector Cell 1) Blocking BCMA receptor 2) Delivery of cytotoxic, MMAF 3) Enhancing antibody- dependent cellular cytotoxicity/phagocytosis 4) Immunogenic cell death gsk DREAMM-5: exploring belantam ab mafodotin combined with y-secretase inhibitors (GSI) Belantamab mafodotin GSI BCMA Cell Death X Belantamab mafodotin 12-0 positive vote at FDA ODAC • Positive opinion adopted by the EMA's CHMP The New York Times FDA Panel Votes in Favor of Approving GSK's Multiple Myeloma Drug REUTERS GSK's blood cancer drug wins European panel thumbs-up Cell Membrane 1) GSI Blocks Shedding of BCMA GSI conc AFGET GSI conc & Y Membrane Internalization -secretase 2) GSI Increases Cell Surface Levels of BCMA 3) GSI Increases Cytotoxic Potency 4) GSI Increases ADCC Potency ARH77 ARH77 ARH77 Come-PE-4:00 RLU (Cell viability) 2.5 10 2-107 1.5-107) 1-107 5-10- 0.0001 0.001 0.01 0.1 Belantamab mafodotin (pg/ml) RLU (ADCC Activity) 800000- 600000- 400000- 200000- 0.01 0.0001 0.001 0.1 GSK2857914 (pg/ml) 10 50

View entire presentation